Well-publicized cases involving children needing cannabis-based treatments to reduce their suffering have led the UK to change its stance on these medicines for patients with an exceptional clinical need.
Home Secretary Sajid Javid has announced that such patients can be prescribed cannabis-derived medicinal products by specialist clinicians from the fall.
He had commissioned a two-part review on June 19 amid public pressure surrounding the cases of Billy Caldwell and Alfie Dingley, young boys who have severe epilepsy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze